Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00387972
Status:
WITHDRAWN
Last Update Posted:
2015-04-17
First Post:
2006-10-12
Brief Title:
Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus T2DM
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Multi-center Double-blind Parallel-group Randomized Placebo-controlled Study to Evaluate the Efficacy Safety and Tolerability of Denagliptin in Subjects With Type 2 Diabetes Mellitus
Status:
WITHDRAWN
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study cancelled before enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
GW823093 is a selective DPP-IV Inhibitor and is being investigated as a once a day oral therapy The purpose of the Study is to evaluate the effectiveness safety and tolerability of 2 doses of GW823093 compared to placebo taken once daily in patients with Type 2 diabetes mellitus
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None